Cambridge Trust Co. boosted its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 15.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 455 shares of the medical instruments supplier’s stock after buying an additional 62 shares during the quarter. Cambridge Trust Co.’s holdings in West Pharmaceutical Services were worth $180,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Fidelis Capital Partners LLC purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at $27,000. Quarry LP increased its position in shares of West Pharmaceutical Services by 155.3% during the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new position in West Pharmaceutical Services in the 1st quarter worth about $40,000. Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services in the 1st quarter worth about $40,000. Finally, ORG Partners LLC boosted its stake in West Pharmaceutical Services by 820.0% in the 1st quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock worth $55,000 after purchasing an additional 123 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.
West Pharmaceutical Services Price Performance
NYSE WST traded down $2.03 during trading hours on Friday, hitting $300.28. The company had a trading volume of 457,026 shares, compared to its average volume of 811,373. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $415.73. The firm has a 50 day simple moving average of $320.53 and a 200 day simple moving average of $354.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34. The firm has a market capitalization of $21.78 billion, a price-to-earnings ratio of 39.61, a PEG ratio of 10.69 and a beta of 1.00.
Insider Activity
In other news, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares in the company, valued at $56,063,718.20. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Articles
- Five stocks we like better than West Pharmaceutical Services
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- EV Stocks and How to Profit from Them
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.